The Expression of Neuroendocrine Markers in a Small Subset of Ameloblastoma with Implications of Clusterin.

Hiromasa Hasegawa, Takanaga Ochiai, Rita R Roy, Katsumitsu Shimada

Abstract read

In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hiromasa HasegawaHard Tissue Pathology Unit, Graduate School of Oral Medicine, Matsumoto Dental University, Shiojiri 399-0781, Japan.ORCID 0000-0001-8222-9658

Takanaga OchiaiHard Tissue Pathology Unit, Graduate School of Oral Medicine, Matsumoto Dental University, Shiojiri 399-0781, Japan.

Rita R RoyDepartment of Physiology, Matsumoto Dental University, Shiojiri 399-078, Japan.ORCID 0000-0002-0285-7265

Katsumitsu ShimadaDepartment of Clinical Pathophysiology, Matsumoto Dental University, Shiojiri 399-078, Japan.ORCID 0009-0002-9786-2581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunohistochemically, ameloblastomas often express CD56; however, novel neuroendocrine markers such as synaptophysin (SYP), insulinoma-associated protein 1 (INSM1), and chromogranin A (CgA) remain unexplored. We analyzed 36 ameloblastoma specimens for CD56, SYP, CgA, and clusterin (CLU) and examined limited samples for INSM1 expression by performing immunohistochemistry, transmission electron microscopy, and reverse transcriptase-polymerase chain reaction. Our findings indicate that the limited cells were positive for CD56, SYP, CgA, INSM1, and CLU expression in 72% (26/36), 14% (5/36), 0% (0/40), 80% (4/5), and 22% (8/36) of the cases, respectively. CD56 expression correlated with older age, but not with subtype, SYP, and CLU expression. However, SYP-positive cases were exclusively found in CD56- and CLU-positive cases, and SYP and CLU expression were significantly correlated. Selected cases had dense-core granules and

Indexed as

AmeloblastomaBiomarkers, TumorClusterinAdolescentAdultAgedCD56 AntigenChildChromogranin AFemaleHumansMaleMiddle AgedRepressor ProteinsSynaptophysinYoung AdultBiomarkers, TumorCD56 AntigenChromogranin ACLU protein, humanClusterinINSM1 protein, humanNCAM1 protein, humanRepressor ProteinsSynaptophysinSYP protein, humanameloblastomaclusterininsulinoma-associated protein 1neuroendocrine differentiationsynaptophysin

Identifiers

PMID39937015

DOI10.3390/cells14030224

PMCPMC11816440

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.